<DOC>
	<DOCNO>NCT01868048</DOCNO>
	<brief_summary>The purpose study determine effective dose range demonstrate non-effective dose range Sativex compare placebo relieve symptom spasticity due multiple sclerosis .</brief_summary>
	<brief_title>Phase 3 , 28-week , Randomized , Double-blind , Placebo-controlled Safety Efficacy Study Nabiximols add-on Therapy Subjects With Spasticity Due Multiple Sclerosis .</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Peppermint oil</mesh_term>
	<criteria>Willing able give write informed consent . The subject least 18 year age old . Diagnosed disease subtype multiple sclerosis least six month duration . Spasticity due multiple sclerosis least six month duration , wholly relieve current antispasticity therapy , expect remain stable duration study . Subject must receive least one follow antispasticity therapy eligible : Baclofen , Tizanidine , Clonazepam , Diazepam , Dantrolene . Subject willing maintain antispasticity medication stable dose duration study stable 30 day prior screen . If subject currently take diseasemodifying medication , must stable dose least three month prior screen visit ; dose must also remain stable duration study . Has previously use Nabiximols Sativex . The subject currently use use cannabis cannabinoid base medication within 30 day study entry unwilling abstain duration study . Any history immediate family history schizophrenia , psychotic illness , severe personality disorder significant psychiatric disorder depression associate underlying condition . In opinion Investigator , know suspected history substance abuse disorder ( include opiate abuse ) , current heavy alcohol consumption ( 60g pure alcohol per day men , 40g pure alcohol per day woman ) , current use illicit drug current non prescribe use prescription drug exclude subject participation . Has poorly control epilepsy recurrent seizure ( i.e . one seizure last year ) . Any known suspected hypersensitivity cannabinoids excipients study medication . Has experience myocardial infarction clinically significant cardiac dysfunction within last 12 month cardiac disorder , opinion investigator would put subject risk clinically significant arrhythmia myocardial infarction . Has significantly impair renal function evidence creatinine clearance lower 50mL/min Visit 1 . Has significantly impair hepatic function Visit 1 ( Alanine Aminotransferase &gt; 5 time upper limit normal ( ULN ) bilirubin ( TBL ) &gt; 2 time ULN ) . If Alanine Aminotransferase Aspartate Aminotransferase &gt; 3 time ULN TBL &gt; 2 time ULN ( International Normalized Ratio &gt; 1.5 ) , subject enter study . Female subject childbearing potential male subject whose partner childbearing potential , unless willing ensure partner use effective contraception complete abstinence , example , oral contraception , double barrier intrauterine device , study three month thereafter ( however , male condom use conjunction female condom may prove effective ) . Female subject pregnant , lactate plan pregnancy course study three month thereafter . Subjects receive nonapproved investigational medicinal product within 30 day Visit 1 . Any significant disease disorder , opinion investigator sponsor , may either put subject risk participation study , may influence result study , subject 's ability participate study . Travel outside country residence plan study . Subjects previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Spasticity</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>